|A review of CMV vaccine development which summarizes the data supporting the feasibility of a prophylactic vaccine against CMV.
||Adler SP. Human CMV vaccine trials: what if CMV caused a rash?. J Clin Virol. 2008;41(3):231-6.
|A Phase II trial of an adjuvanted recombinant gB protein with projected 50% efficacy against congenital transmission of CMV.
||Pass RF, Zhang C, Evans A, et al. Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med. 2009;360(12):1191-9.
|An analysis of samples from the clinical trial of adjuvanted gB protein (Pass RF 2009) demonstrates that the vaccine induced nAb titers were able to prevent fibroblast cell infection comparable to naturally acquired immunity; however, titers were approximately ten times below naturally acquired immunity against CMV infection of epithelial cells.
||Cui X, Meza BP, Adler SP, Mcvoy MA. Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection. Vaccine. 2008;26(45):5760-6.
|A phase II trial of an adjuvanted recombinant gB protein in the solid organ transplant setting with evidence of efficacy including reduced viremia and reduced duration of anti-viral treatment.
||Griffiths PD, Stanton A, Mccarrell E, et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet. 2011;377(9773):1256-63.
|nAbs against gB, but not components of the pentameric complex, are capable of preventing CMV infection of placental trophoblast progenitor cells – a critical cell type infected during congenital transmission of CMV.
||Zydek M, Petitt M, Fang-hoover J, et al. HCMV infection of human trophoblast progenitor cells of the placenta is neutralized by a human monoclonal antibody to glycoprotein B and not by antibodies to the pentamer complex. Viruses. 2014;6(3):1346-64.